Ventricular tachycardia (VT, or “vtach”) is treated based on how stable the person is at that moment. If blood pressure is crashing or the person loses consciousness, the immediate priority is an electrical shock to reset the heart’s rhythm. If the person is stable with a pulse and adequate blood pressure, medications are typically the first step. After the acute episode is controlled, long-term treatment focuses on preventing it from happening again, often with a combination of medication, implantable devices, and sometimes a procedure to destroy the abnormal tissue causing the problem.
Emergency Treatment for Unstable VT
When vtach causes dangerously low blood pressure, chest pain, or altered consciousness, the treatment is synchronized cardioversion: a controlled electrical shock delivered through pads on the chest. The initial energy level is typically 50 joules. If that doesn’t work, the energy is doubled with each attempt, reaching up to 200 joules after about three shocks. This is different from defibrillation used in cardiac arrest, where unsynchronized, higher-energy shocks are used. In synchronized cardioversion, the shock is timed to land at a specific point in the heart’s electrical cycle to avoid triggering a worse rhythm.
If VT deteriorates into ventricular fibrillation (where the heart quivers instead of pumping), or if the person has no pulse, standard cardiac arrest protocols take over with CPR, defibrillation, and emergency medications.
Medications During an Acute Episode
For stable VT, where the person is conscious with adequate blood pressure, IV medications are the typical first-line approach. The main drugs used in a hospital setting work by slowing the abnormal electrical signals in the heart. Procainamide, for example, is given as an IV loading dose at a rate of 20 to 50 milligrams per minute, with a continuous infusion afterward to maintain effect. Amiodarone and lidocaine are also commonly used in emergency settings, each with different strengths depending on the type of VT and the patient’s underlying heart condition.
These medications buy time. They can break the abnormal rhythm and keep it from returning in the short term, but they aren’t usually the whole answer. Once the immediate crisis is resolved, the medical team shifts to figuring out why the VT happened and how to prevent it from coming back.
Finding and Fixing Reversible Causes
Before committing to long-term treatment, doctors look for reversible triggers that could have set off the episode. Emergency teams use a checklist known as the “Hs and Ts” to systematically work through possibilities:
- Hypoxia: low oxygen levels
- Hypovolemia: not enough fluid or blood volume
- Hypothermia: dangerously low body temperature
- Hypo/hyperkalemia: abnormal potassium levels, which directly affect heart rhythm
- Tension pneumothorax: a collapsed lung putting pressure on the heart
- Cardiac tamponade: fluid compressing the heart
- Toxins: drug overdoses or poisoning
- Thrombosis: blood clots in the heart or lungs
If a reversible cause is found, correcting it may be all that’s needed. A potassium imbalance, for instance, can trigger vtach that resolves completely once levels are normalized. But when VT stems from structural heart disease, like scar tissue from a prior heart attack, the treatment plan becomes more involved.
Implantable Defibrillators for Long-Term Protection
An implantable cardioverter-defibrillator (ICD) is a small device placed under the skin near the collarbone, with wires threaded into the heart. It continuously monitors the heart’s rhythm and delivers a shock automatically if it detects a dangerous arrhythmia. For many VT patients, this is the cornerstone of long-term treatment.
ICDs are recommended for two broad groups. The first is people who have already survived a life-threatening VT episode or cardiac arrest. The landmark AVID trial showed that ICDs improved overall survival compared to medication alone in these patients. An ICD is also warranted for people who’ve fainted and have VT that can be triggered during testing in the electrophysiology lab, even if they don’t otherwise meet standard criteria.
The second group is people who haven’t had a VT episode yet but are at high risk. The main indicator is a weakened heart, specifically a pumping capacity (ejection fraction) of 35% or below, combined with heart failure symptoms despite being on optimal medication. For people whose weak heart stems from a prior heart attack, guidelines recommend waiting at least 40 days after the event before placing an ICD, since studies showed no survival benefit from implanting one earlier. For people with heart muscle disease unrelated to blocked arteries, at least three months on heart failure medication is recommended before making the ICD decision, because the heart sometimes recovers enough on medication alone.
Beta-Blockers and Ongoing Medication
Beta-blockers are a mainstay of long-term VT prevention. They work by reducing the heart’s workload and dampening the electrical excitability that triggers abnormal rhythms. Guidelines recommend pushing the dose as high as a patient can tolerate, with target daily doses of 200 mg for metoprolol or 50 mg for carvedilol. In practice, only about a third of patients actually reach these target doses, often because of side effects like fatigue, dizziness, or low blood pressure.
A Danish nationwide study of ICD patients found that higher beta-blocker doses were associated with better outcomes, including fewer episodes of dangerous heart rhythms and fewer heart failure hospitalizations. This makes dose optimization an important conversation to have with your cardiologist. If side effects are limiting your dose, switching between different beta-blockers sometimes helps, since they have slightly different profiles.
Antiarrhythmic medications like amiodarone are sometimes added on top of beta-blockers, particularly for patients who continue having VT episodes despite an ICD. These drugs carry their own side effects with long-term use, so they’re generally reserved for situations where other approaches aren’t enough.
Catheter Ablation
Catheter ablation is a procedure where a specialist threads a thin tube through a blood vessel into the heart and uses heat or cold energy to destroy the small areas of tissue responsible for generating the abnormal rhythm. It’s typically offered when medications aren’t controlling VT well enough or when an ICD is delivering frequent shocks.
Success rates vary considerably depending on the underlying heart condition. In the SMASH-VT study, 88% of patients with heart attack-related scarring were free from VT recurrence two years after ablation, compared to 67% of those treated without ablation. The VTACH trial found a more modest 47% VT-free survival at two years, reflecting differences in how sick the patients were going in. For patients with the most advanced disease and frequent ICD shocks, outcomes are less favorable: one trial found 62% had VT recur within just six months.
The type of heart disease matters significantly. Patients whose VT originates from heart attack scarring tend to do better than those with other types of heart muscle disease. One study found one-year VT-free survival of 57% for heart attack patients versus 40.5% for those with non-ischemic cardiomyopathy. For certain genetic conditions like arrhythmogenic right ventricular cardiomyopathy (ARVC), ablation from both inside and outside the heart (an endo-epicardial approach) dramatically improved results: 84.6% VT-free survival at three years versus 52.2% with inside-only ablation.
Ablation often requires more than one procedure. Some patients do well after a single session, while others need repeat ablations as new areas of abnormal tissue become active over time.
Activity and Lifestyle After VT
After a VT episode or ICD placement, most people face some restrictions on physical activity, at least temporarily. The specifics depend on the underlying cause. For conditions like ARVC, guidelines recommend avoiding competitive and endurance sports entirely, and research supports dramatically reducing exercise intensity and duration rather than just limiting how long you work out. Reducing both the intensity and the total amount of exercise appears more important than cutting back on just one or the other.
For VT related to other causes, activity recommendations are more individualized. Cardiac rehabilitation programs can help you find a safe exercise level while rebuilding fitness under monitored conditions. Driving restrictions also apply after a VT episode or ICD shock in most jurisdictions, typically ranging from a few weeks to six months depending on local regulations and whether you drive commercially.
Ongoing follow-up with a cardiologist or electrophysiologist is a permanent part of life after VT. ICD patients typically have their device checked every three to six months, either in person or through remote monitoring. Medication adjustments are common in the first year as doctors fine-tune the balance between rhythm control and side effects.